Analysts Set TScan Therapeutics, Inc. (NASDAQ:TCRX) PT at $6.60

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) have been assigned an average recommendation of “Hold” from the seven research firms that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $6.60.

A number of brokerages have issued reports on TCRX. BTIG Research lowered TScan Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday, November 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of TScan Therapeutics in a report on Thursday, January 22nd. Needham & Company LLC reduced their price objective on shares of TScan Therapeutics from $9.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, November 4th. HC Wainwright dropped their target price on shares of TScan Therapeutics from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Thursday, November 13th. Finally, Morgan Stanley lowered shares of TScan Therapeutics from an “overweight” rating to an “equal weight” rating in a research note on Friday, November 14th.

Insider Buying and Selling at TScan Therapeutics

In other TScan Therapeutics news, major shareholder Lynx1 Capital Management Lp acquired 75,500 shares of the company’s stock in a transaction that occurred on Monday, December 22nd. The shares were purchased at an average price of $0.90 per share, for a total transaction of $67,950.00. Following the completion of the purchase, the insider directly owned 8,012,916 shares in the company, valued at $7,211,624.40. The trade was a 0.95% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Insiders have acquired 161,801 shares of company stock worth $145,621 over the last 90 days. 4.35% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Catalyst Funds Management Pty Ltd acquired a new stake in TScan Therapeutics in the second quarter worth approximately $26,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of TScan Therapeutics in the second quarter valued at $29,000. Quadrature Capital Ltd bought a new position in TScan Therapeutics during the second quarter valued at about $33,000. Boothbay Fund Management LLC grew its holdings in TScan Therapeutics by 50.0% during the second quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock worth $35,000 after acquiring an additional 8,121 shares during the period. Finally, Marshall Wace LLP bought a new stake in TScan Therapeutics in the second quarter worth about $78,000. 82.83% of the stock is owned by institutional investors and hedge funds.

TScan Therapeutics Trading Down 0.9%

Shares of TCRX opened at $1.12 on Friday. TScan Therapeutics has a twelve month low of $0.88 and a twelve month high of $2.67. The firm has a market capitalization of $63.56 million, a P/E ratio of -1.00 and a beta of 1.04. The company has a current ratio of 6.44, a quick ratio of 6.44 and a debt-to-equity ratio of 0.23. The stock’s fifty day simple moving average is $1.06 and its 200 day simple moving average is $1.54.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.07. The company had revenue of $2.51 million during the quarter, compared to the consensus estimate of $1.98 million. TScan Therapeutics had a negative net margin of 1,692.96% and a negative return on equity of 73.33%. On average, equities research analysts forecast that TScan Therapeutics will post -1.12 earnings per share for the current year.

About TScan Therapeutics

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.